MCL1 and glioblastoma: Our observations emphasize the necessity to investigate Mcl-1 expression levels prior to the therapeutic utilization of TRAIL in GBM patients, especially when one considers the high levels of Mcl-1 expression reported in tumours isolated from such patients [4].